logo
3 Growth Stocks That Turned $5,000 Investments 20 Years Ago Into Over $1 Million Today

3 Growth Stocks That Turned $5,000 Investments 20 Years Ago Into Over $1 Million Today

Globe and Mail6 hours ago

Investing in growth stocks can lead to significant long-run returns. It isn't always evident, however, how a company's future will pan out. Some businesses that look like surefire winners will end up failing. Others will benefit from unexpected catalysts, such as artificial intelligence (AI), that you couldn't have predicted when you first invested in them.
That's why investing in multiple growth stocks can be a great idea because all you need is one big winner, one huge return to make it worth your while. Three stocks that are excellent examples of how just a single investment can yield life-changing returns are Nvidia (NASDAQ: NVDA), Netflix (NASDAQ: NFLX), and Booking Holdings (NASDAQ: BKNG). By investing just $5,000 into any of these stocks 20 years ago and hanging on until today, you would be up more than $1 million.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Nvidia
One of the biggest growth stories in recent years has been that of chipmaker Nvidia. It has made many millionaires as its business has taken off due to AI. Its chips are no longer used for just gaming, but are now critical in the development of AI technologies, including chatbots.
While Nvidia has been a solid growth stock for years, things have gone to a whole other level since ChatGPT came on the scene in late 2022. That led to a flurry of tech spending and AI-related investments. In the trailing 12 months, Nvidia has generated a whopping $77 billion in profit. Just a few years ago it wasn't even bringing in that much in revenue.
As a leading AI chipmaker, Nvidia still possesses a lot of long-term potential, which is why as long as you're looking for a stock to buy and hold, you're likely better off buying now than hoping for a big dip in price. If you'd invested $5,000 into this stock 20 years ago, you'd be sitting on an investment worth more than $3.1 million today.
Netflix
The trajectory for Netflix has been more consistent over the years, with the company revolutionizing its business model over time under great management. It went from mailing out DVDs to customers to offering streaming to now getting into live TV, sports, and even gaming. It has even been making its own content, as a way to expand its library and be less dependent on studios for licensing deals.
The company is now a $40 billion business, and a highly profitable one, with net margins of more than 23%. It has been the model that other companies look to as proof that the streaming business can indeed be lucrative.
It has pushed through multiple price hikes over the years and cracked down on password sharing, and while those moves may have appeared controversial when they took place, they have clearly paid off for the business, simply because Netflix provides consumers with such an attractive value proposition.
A $5,000 investment in the company 20 years ago would now be worth about $3 million, not far behind Nvidia. Although the streaming stock is trading at all-time highs, Netflix can still make for a good long-term investment as it continually finds ways to expand.
Booking Holdings
Another millionaire-making investment during the past 20 years has been Booking Holdings. Just a $5,000 investment in the company back then would have grown to a little less than $1.1 million today.
The company is a leader in online travel sites and services. When you're looking to book online travel, you may find yourself using one of its highly popular websites -- kayak.com, priceline.com, or booking.com. The internet has revolutionized travel and what decades ago involved calling or seeing a travel agent can now easily be done online, potentially soon via AI agents. And to compare prices, websites like the ones Booking owns can ensure you're getting the best deal out there.
Last year, the company generated $23.7 billion in sales (up more than 11% from the previous year), earning a profit of $5.9 billion. And while the business has grown significantly over the years, it doesn't look all that expensive given its growth potential, trading at 33 times its trailing earnings. The business has great margins and can be an excellent way to invest in the travel industry.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $676,023!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,692!*
Now, it's worth noting Stock Advisor 's total average return is793% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cloudflare Expands AI Tools: Will Revenue Growth Follow?
Cloudflare Expands AI Tools: Will Revenue Growth Follow?

Globe and Mail

time39 minutes ago

  • Globe and Mail

Cloudflare Expands AI Tools: Will Revenue Growth Follow?

Cloudflare NET is implementing artificial intelligence (AI) initiatives across its portfolio and experiencing strong traction across AI Gateway, Workers AI and Durable Objects and Containers solutions. In the first quarter of fiscal 2025, NET reported a whopping year-over-year rise of 4,000% in its Workers AI inference requests and a 1,200% increase in AI Gateway requests. Cloudflare is further augmenting its solutions by implementing AI across its infrastructure and security suite. The company has launched the Model Context Protocol server, which is embedded inside the Workers Platform to ease the deployment of AI agents to streamline workflows, handle transactions, and simplify business data queries. This value addition has the potential to increase upsells and customer acquisition. Another recent addition to NET's portfolio is Cloudflare for AI, which is designed to enable businesses to adopt AI responsibly and at scale. The solution includes Data Loss Prevention for AI, which prevents sensitive data from leaking through prompts or model outputs; an AI Gateway, a fully-managed vector database for semantic search named Vectorize and Access for AI with Zero Trust controls. Global giants like Asana, Atlassian, Block, PayPal, Sentry, and Stripe are already working with Cloudflare to create powerful AI experiences. After the implementation of AI capabilities in its portfolio, Cloudflare expects to win several large deals. Cloudflare already had 250,819 paying customers at the end of the first quarter of fiscal 2025, up 27% year over year. NET added 30 new customers during the quarter that contributed more than $100,000 in annual revenues, taking the count of such customers to 3,527 at the end of the quarter. For 2025, Cloudflare anticipates its revenues between $2.09 billion and $2.094 billion. The Zacks Consensus Estimate for the same is pegged at $2.09 billion, indicating a year-over-year rise of 25.38%. How Competitors Fare Against Cloudflare Cloudflare faces competition in multiple dimensions from Amazon AMZN. Amazon Web Services' ('AWS') Lambda, Bedrock, SageMaker, and API Gateway make it a direct competitor of Cloudflare in the serverless computing and AI inference space. AWS also offers vector databases and cybersecurity services like Cloudflare. Alphabet 's GOOGL Vertex AI, Cloud Run, Firebase, and AI/ML APIs, Google Cloud Platform offers solutions for AI development, model inference, and low-latency app deployment, making Alphabet a strong contender for Cloudflare. Cloudflare's AI initiatives have brought it head-on with cloud hyperscalers like Alphabet and Amazon in infrastructure and inference hosting, with enterprises switching to Cloudflare platform for its better performance, lower development cost and modernized platform. These factors will help NET boost its revenues. Cloudflare's Price Performance, Valuation and Estimates Shares of NET have surged 73.2% year to date compared with the Zacks Internet - Software industry's growth of 15.4%. From a valuation standpoint, NET trades at a forward price-to-sales ratio of 27.42X, higher than the industry's average of 5.8X. The Zacks Consensus Estimate for NET's 2025 and 2026 earnings implies year-over-year growth of 5.33% and 31.64%, respectively. The estimates for 2025 and 2026 earnings have been revised downward in the past 60 days and 30 days, respectively. NET currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Cloudflare, Inc. (NET): Free Stock Analysis Report

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

Globe and Mail

time39 minutes ago

  • Globe and Mail

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. Legacy Portfolio is adversely impacted due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Sales of blood thinner medicine Eliquis were down 4% in the first quarter due to the impact of Medicare Part D redesign in the United States. In such a scenario, the performance of new drugs is key to BMY's growth. Thalassemia drug, Reblozyl, has put up a stellar performance, driven by strong growth in the first and second-line treatment of myelodysplastic syndromes (MDS)-associated anemia. The drug should contribute significantly in the coming decade. Revenue growth has been good for the leading immuno-oncology drug Opdivo, driven primarily by volume growth. Sales of CAR T cell therapy, Breyanzi, also continue to gain traction from the approval of new indications and expanded manufacturing capacity. Camzyos has also witnessed strong global uptake in obstructive HCM. BMY had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. Competition for BMY's Key Drugs Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. The immuno-oncology space is dominated by pharma giant Merck 's MRK blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 50% of MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer PFE is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Last month, Pfizer inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China. BMY is also trying to develop bispecific antibodies. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 15% year to date compared with the industry 's decline of 3.4%. From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.34x forward earnings, lower than its mean of 8.54x and the large-cap pharma industry's 14.79X. The Zacks Consensus Estimate for 2025 and 2026 earnings per share has moved south in the past 60 days. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report

Beeline Holdings (NASDAQ: BLNE) Subsidiary Closes Crypto-Backed Real Estate Deal
Beeline Holdings (NASDAQ: BLNE) Subsidiary Closes Crypto-Backed Real Estate Deal

Globe and Mail

timean hour ago

  • Globe and Mail

Beeline Holdings (NASDAQ: BLNE) Subsidiary Closes Crypto-Backed Real Estate Deal

Beeline Holdings (NASDAQ: BLNE), a digital mortgage platform, announced that its subsidiary Beeline Title Holdings, Inc. has completed what it believes to be one of the first residential real estate closings funded via a cryptocurrency token backed by real property. The milestone marks a significant step in merging blockchain finance with traditional title and escrow services. Beeline aims to expand its crypto-enabled platform to all lenders, offering infrastructure for compliant transaction disbursement and reconciliation. The company plans to launch a fractional equity sale product in August 2025 through Beeline Loans, Inc., with Beeline Title handling closings. To view the full press release, visit About Beeline Financial Holdings, Inc. Beeline Financial Holdings, Inc. is a trailblazing mortgage fintech transforming the way people access property financing. Through its fully digital, AI-powered platform, Beeline delivers a faster, smarter path to home loans—whether for primary residences or investment properties. Headquartered in Providence, Rhode Island, Beeline is reshaping mortgage origination with speed, simplicity, and transparency at its core. The company is a wholly owned subsidiary of Beeline Holdings and also operates Beeline Labs, its innovation arm focused on next-generation lending solutions. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store